A version of this article first ran in D.C. Diagnosis, STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.
WASHINGTON — Here in the nation’s capital, the consensus is that the coronavirus pandemic has quashed all hope of serious drug pricing reform, at least for the foreseeable future. But states around the country have enacted significant reforms over the last month, even while they were dealing with a crisis.